Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand

International Journal of Cancer

Volumn 108, Issue 5, 2004, Pages 696-703

  Huang, Hsing I ^a   Wu, Ping Yi ^a   Teo, Chin Yee ^a   Chen, Min Nan ^a,b   Chen, Yi Chau ^a   Silin, Dmytro ^a   Tao, Mi Hua ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

B cell lymphoma; CD40 ligand; Idiotype; Tumor vaccine

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; HYBRID PROTEIN; ID CD40 LIGAND; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER IMMUNIZATION; CONCENTRATION RESPONSE; COVALENT BOND; CYTOKINE PRODUCTION; IMMUNOGENICITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; TUMOR; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD40 LIGAND; IMMUNITY, CELLULAR; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 0347285398     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11612     Document Type: Article

References (53)

1. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14:591-617.
2. Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol 1996;63:43-78.
3. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35.
4. + T-helper and a T-killer cell. Nature 1998;393:474-8.
5. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
6. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
7. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-6.
8. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-52.
9. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774-9.
10. Lefrancois L, Olson S, Masopust D. A critical role for CD40-CD40 ligand interactions in amplification of the mucosal CD8 T cell response. J Exp Med 1999;190:1275-84.
11. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7.
12. Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol 2000;164:1230-5.
13. Lefrancois L, Altman JD, Williams K, Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 2000;164:725-32.
14. Perez-Melgosa M, Hollenbaugh D, Wilson CB. Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. J Immunol 1999;163:1123-7.
15. Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J Immunol 2000;164:5913-21.
16. Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2001;7:136-43.
17. Erickson LD, Durell BG, Vogel LA, O'Connor BP, Cascalho M, Yasui T, Kikutani H, Noelle RJ. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002;109:613-20.
18. Mehling A, Loser K, Varga G, Metze D, Luger TA, Schwarz T, Grabbe S, Beissert S. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001;194:615-28.
19. Santos-Argumedo L, Alvarez-Maya I, Romero-Ramirez H, Flores-Romo L. Enforced and prolonged CD40 ligand expression triggers autoantibody production in vivo. Eur J Immunol 2001;31:3484-92.
20. Higuchi T, Aiba Y, Nomura T, Matsuda J, Mochida K, Suzuki M, Kikutani H, Honjo T, Nishioka K, Tsubata T. Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 2002;168:9-12.
21. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-33.
22. George AJ, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988;141:2168-74.
23. King CA, Spellerberg MB, Zhu DL, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281-6.
24. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-8.
25. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994;153:4775-87.
26. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-11.
27. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-8.
28. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-53.
29. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977;7:413-7.
30. Huang TH, Wu PY, Lee CN, Huang HI, Hsieh SL, Kung J, Tao MH. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen. Blood 2000;96:3663-70.
31. Liu SJ, Sher YP, Ting CC, Liao KW, Yu CP, Tao MH. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 1998;92:2103-12.
32. Fortier AH, Falk LA. Macrophages and monocytes. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current protocols in immunology. New York: John Wiley and Sons, 1997. 14.1.1-9.
33. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
34. Chen HW, Huang HI, Lee YP, Chen LL, Liu HK, Cheng ML, Tsai JP, Tao MH, Ting CC. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment. Cancer Immunol Immunother 2002;51:341-8.
35. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, Thomas D. A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995;3:1426.
36. Bajorath J, Marken JS, Chalupny NJ, Spoon TL, Siadak AW, Gordon M, Noelle RJ, Hollenbaugh D, Aruffo A. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry 1995;34:9884-92.
37. Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 1994;6:267-78.
38. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998;160:1320-9.
39. + T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 2001;28:28.
40. Kawamura H, Berzofsky JA. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to antiimmunoglobulin. J Immunol 1986;136:58-65.
41. Snider DP, Kaubisch A, Segal DM. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 1990;171:1957-63.
42. Carayanniotis G, Skea DL, Luscher MA, Barber BH. Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Mol Immunol 1991;28:261-7.
43. Wernersson S, Karlsson MC, Dahlstrom J, Mattsson R, Verbeek JS, Heyman B. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. J Immunol 1999;163:618-22.
44. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53.
45. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002;168:2720-8.
46. Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res 2000;60:3225-31.
47. Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today 1999;20:488-93.
48. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93:2999-3007.
49. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61:7556-62.
50. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H. Anti-CD40 antibody induces antitumor and anti-metastatic effects: the role of NK cells. J Immunol 2001;166:89-94.
51. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002;99:5561-6.
52. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:102936.
53. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999;162:4790-5.